New cancer drug shows promise in first trial outside the US

March 10, 2014 by Alison Barbuti , University of Manchester

(Medical Xpress)—A cancer patient from Bolton with a rare form of Non-Hodgkin's Lymphoma is in remission after becoming the first person outside of the US to trial a new cancer drug, Brentuximab Vedotin, led by University of Manchester Professor at The Christie Hospital in Manchester.

Ian Brooks was first diagnosed with Anaplastic Large Cell Lymphoma, a rare and aggressive form of Non-Hodgkin's Lymphoma, in 2001 and despite an initial positive response to treatment the returned in 2008.

He underwent a , but the cancer came back again and spread throughout his body.

With few options remaining, and given just weeks to live he volunteered to take part in the trial for the Brentuximab Vedotin.

Within just 24 hours of starting the drug, Mr Brooks began to show improvements and after just two weeks his consultants at The Christie Hospital were amazed to see his scan showed he was clear of tumours.

The drug acts like an 'armour piercing shell' and destroys cells from the inside, puts patients into 'deep remission' when there would otherwise be few treatment options available to them.

Professor Tim Illidge, Professor of Targeted Therapy and Oncology in the Institute of Cancer Studies, who led the trial noted: "Brentuximab has a remarkably novel mode of action which bodes well for future . The antibody is combined with an anti-cancer drug called Vedotin, so powerful that it cannot be used in standard chemotherapy.

"The antibody targets the protein on the cancer cell, called CD30, and then it delivers Vedotin straight to the tumour."

Mr Brooks said: "I don't think I would be here today without that drug. My specialist at the hospital was so excited when he saw the results that he came and showed me the results straight away. I had 60 or 70 tumours and they had gone.

"I can't thank the NHS and the hospital enough for what they have done for me. Everybody has been wonderful. Hopefully my taking part in this trial will help other people."

The trial at The Christie has proved so successful that the drug is now routinely available for NHS patients with the same rare condition through the Cancer Drugs Fund.

Dr Adam Gibb, Clinical Research Fellow in Lymphoma at The Christie Hospital and Honorary member of the Institute of Cancer Sciences, said: "The drug can be administered rapidly and has few side effects. This is probably the most impressive set of scans I've seen. Ian was really up against it. He is in remission and we are increasingly confident about him.

Explore further: Drug-antibody pair has promising activity in non-Hodgkin lymphoma

Related Stories

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

December 10, 2013
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

Cancer Research UK launches trial of new lymphoma treatment

January 29, 2014
Cancer Research UK's Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body's own immune system to attack cancerous B-cells growing out of control.

Brentuximab vedotin effective in large-cell lymphoma

May 24, 2012
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, ...

Scientists explore promising new option for first line of attack in lymphoma

February 25, 2014
Follicular lymphoma is a type of non-Hodgkin's lymphoma– a blood cancer - that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

New drug dramatically improves survival in Hodgkin lymphoma patients

June 27, 2012
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

Targeted treatment is better than chemotherapy in some lung cancer patients

January 13, 2014
(Medical Xpress)—Patients with lung cancer who also have a specific gene rearrangement do better on a new targeted therapy compared with standard chemotherapy, according a study by University of Manchester scientists.

Recommended for you

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.